No­var­tis drums up an­tic­i­pa­tion for block­buster-to-be with PhII da­ta on asth­ma drug, beat­ing Ad­vair in head-to-head

An asth­ma drug that No­var­tis has tapped as a big mon­ey­mak­er has de­liv­ered a clean sweep in Phase II, boost­ing its block­buster case months ahead of a Phase III read­out.

The two stud­ies com­pared QVM149 to Glax­o­SmithK­line’s Ad­vair and place­bo, re­spec­tive­ly. Re­sults sug­gest that the in­haled triple — in­da­caterol ac­etate, gly­copy­rro­ni­um bro­mide and mometa­sone furoate de­liv­ered with the Breezhaler de­vice — beat both in im­prov­ing lung func­tion, as cap­tured by vari­a­tions of the forced ex­pi­ra­to­ry vol­ume in 1 sec­ond (FEV1) met­ric.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER